Business Context and Reporting Period
This filing is a Form 6-K transaction notification for GlaxoSmithKline plc (GSK) covering transactions executed on February 20, 2017, and February 21, 2017. The document details share transactions by Persons Discharging Managerial Responsibilities (PDMRs) and persons closely associated with them, specifically related to the exercise of nil-cost options and subsequent sales to meet tax liabilities under the Company's 2009 Deferred Annual Bonus Plan.
Key Financial Metrics and Transaction Details
The filing does not contain corporate financial statements (revenue, profit, cash flow, or debt). It reports specific equity transactions involving the following executives:
- Sir Andrew Witty (CEO): Exercised options for 90,448 shares at £0.00; sold 42,531 shares at approx. £16.34 to cover taxes.
- Ms. E. Walmsley (CEO Designate): Exercised options for 19,814 shares at £0.00; sold 9,316 shares at approx. £16.35 to cover taxes.
- Mr. D. S. Redfern (Chief Strategy Officer): Exercised options for 16,154 shares at £0.00; sold 7,746 shares at approx. £16.34 to cover taxes.
- Ms. C. Thomas (SVP, Human Resources): Exercised options for 10,023 shares at £0.00; sold 4,806 shares at approx. £16.37 to cover taxes.
- Mr. P. C. Thomson (SVP, Communications & Government Affairs): Exercised options for 6,037 shares at £0.00; sold 2,895 shares at approx. £16.35 to cover taxes.
All sales were conducted on the London Stock Exchange (XLON). The filing text does not provide a clear value for total corporate liquidity, margins, or debt levels.
Material Changes Versus Prior Period
This filing is a discrete transaction notification and does not provide comparative financial data or material changes in business operations versus a prior comparable period.
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, or discussion of risks and contingencies. The transactions are routine exercises of deferred bonus awards and matching awards granted on February 12, 2014.
Important Facts for Investor Verification
- Verify the total number of shares sold by executives to cover tax liabilities versus the number of shares retained.
- Confirm the market price of GSK ordinary shares on February 20 and 21, 2017, to validate the transaction prices (approx. £16.33–£16.37).
- Note the transition of leadership roles, specifically Ms. E. Walmsley's status as "CEO Designate" at the time of these transactions.
- Confirm that these transactions were executed under the 2009 Deferred Annual Bonus Plan and were not discretionary open-market sales.